Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0155 Transporter Info
Gene Name	SLC22B3
Transporter Name	Synaptic vesicle glycoprotein 2C
Gene ID	22987
UniProt ID	Q496J9

Post-Translational Modification of This DT
Overview of SLC22B3 Modification Sites with Functional and Structural Information
Sequence	M E D S Y K D R T S L M K G A K D I A R E V K K Q T V K K V N Q A V D R A Q D E Y T Q R S Y S R F Q D E E D D D D Y Y P A G E T Y N G E A N D D E G S S E A T E G H D E D D E I Y E G E Y Q G I P S M N Q A K D S I V S V G Q P K G D E Y K D R R E L E S E R R A D E E E L A Q Q Y E L I I Q E C G H G R F Q W A L F F V L G M A L M A D G V E V F V V G F V L P S A E T D L C I P N S G S G W L G S I V Y L G M M V G A F F W G G L A D K V G R K Q S L L I C M S V N G F F A F L S S F V Q G Y G F F L F C R L L S G F G I G G A I P T V F S Y F A E V L A R E K R G E H L S W L C M F W M I G G I Y A S A M A W A I I P H Y G W S F S M G S A Y Q F H S W R V F V I V C A L P C V S S V V A L T F M P E S P R F L L E V G K H D E A W M I L K L I H D T N M R A R G Q P E K V F T V N K I K T P K Q I D E L I E I E S D T G T W Y R R C F V R I R T E L Y G I W L T F M R C F N Y P V R D N T I K L T I V W F T L S F G Y Y G L S V W F P D V I K P L Q S D E Y A L L T R N V E R D K Y A N F T I N F T M E N Q I H T G M E Y D N G R F I G V K F K S V T F K D S V F K S C T F E D V T S V N T Y F K N C T F I D T V F D N T D F E P Y K F I D S E F K N C S F F H N K T G C Q I T F D D D Y S A Y W I Y F V N F L G T L A V L P G N I V S A L L M D R I G R L T M L G G S M V L S G I S C F F L W F G T S E S M M I G M L C L Y N G L T I S A W N S L D V V T V E L Y P T D R R A T G F G F L N A L C K A A A V L G N L I F G S L V S I T K S I P I L L A S T V L V C G G L V G L C L P D T R T Q V L M
PTM type	X-N-glycosylation X-Oxidation X-Phosphorylation X: Amino Acid

N-glycosylation
Asparagine	5 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Increasing the affinity of SLC22B3			[1]
Role of PTM	Protein Activity Modulation
Modified Residue	Asparagine	Modified Location	559
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-glycosylation at SLC22B3 Asparagine 559 have been reported to increase its transport affinity.
PTM Phenomenon 2	No significant impaired transporter			[1]
Role of PTM	No Significant Effect
Modified Residue	Asparagine	Modified Location	534
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-glycosylation at SLC22B3 Asparagine 534 have been reported to have no significant effect on its expression or subcellular localisation, nor did it affect the rate of drug transport.
PTM Phenomenon 3	No significant impaired transporter			[1]
Role of PTM	No Significant Effect
Modified Residue	Asparagine	Modified Location	565
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-glycosylation at SLC22B3 Asparagine 565 have been reported to have no significant effect on its expression or subcellular localisation, nor did it affect the rate of drug transport.
PTM Phenomenon 4	Have the potential to influence SLC22B3			[2]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	480
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC22B3 Asparagine 480 has the potential to affect its expression or activity.
PTM Phenomenon 5	Have the potential to influence SLC22B3			[2]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	484
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC22B3 Asparagine 484 has the potential to affect its expression or activity.
Oxidation
Cystine	3 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SV2C			[3]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	145
Experimental Method	Co-Immunoprecipitation
Detailed Description	Oxidation at SV2C Cystine 145 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SV2C			[3]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	424
Experimental Method	Co-Immunoprecipitation
Detailed Description	Oxidation at SV2C Cystine 424 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SV2C			[3]
Role of PTM	Potential impacts
Modified Residue	Cystine	Modified Location	678
Experimental Method	Co-Immunoprecipitation
Detailed Description	Oxidation at SV2C Cystine 678 has the potential to affect its expression or activity.
Phosphorylation
Serine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC22B3			[4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	108
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC22B3 Serine 108 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC22B3			[5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	515
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC22B3 Serine 515 has the potential to affect its expression or activity.
Tyrosine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC22B3			[6]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	41
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC22B3 Tyrosine 41 has the potential to affect its expression or activity.

References
1	Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C mediates high affinity binding to botulinum neurotoxin serotype A1. Biochem J. 2016 Sep 1;473(17):2645-54.
2	dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. Nucleic Acids Res. 2022 Jan 7;50(D1):D471-D479. (ID: SV2C_HUMAN)
3	A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging. Cell. 2020 Mar 5;180(5):968-983.e24.
4	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell. 2016 Aug 11;166(4):1041-1054.
5	iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012 Jun;11(6):M111.014423.
6	Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts. PLoS Comput Biol. 2015 Apr 17;11(4):e1004130.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence